Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune, neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment. Standard therapies for CIPD have been recommended for decades, however, there are many unmet needs related to these therapies. New and emerging treatment data show promising results with potentially safer, more efficacious treatments that could change practice guidelines and improve patient outcomes. The multidisciplinary healthcare team treating patients with CIDP will benefit from education on CIDP, the data behind current guideline-directed treatment and emerging data and outcomes for upcoming treatments that may improve patient outcomes and raise the standard of care.
In this CME Outfitters Journal Club, expert faculty will present and discuss the very latest research abstracts from the 2024 Peripheral Nerve Society Annual Meeting (June 2024), including the latest research on the role of the complement system in CIPD, clinical and electrophysical variants of CIDP, and standard vs. emerging treatment options for CIDP.
At the conclusion of this activity, learners will be able to better:
This activity is supported by educational grants from argenx and Sanofi.
Global neurologists, neuromuscular specialists, physician associates (PAs), nurse practitioners (NPs), and nurses
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 08/29/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Querol‘s comments are his own. He reports the following financial relationships:
Advisory Board: argenx; CSL Behring; Dianthus Therapeutics; Nuvig Therapeutics, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and UCB Pharma S.A.
Consultant: Alnylam Pharmaceuticals, Inc.; Annexon, Inc.; argenx; Avilar Therapeutics, Inc.; CSL Behring; Dianthus Therapeutics; Lycia Therapeutics; Merck & Co., Inc.; Novartis AG; Nuvig Therapeutics, Inc.; Roche; Sanofi; Takeda Pharmaceutical Company Limited; and UCB Pharma S.A.
Research Support: argenx; CIBERER; Fundació La Marató; Instituto de Salud Carlos III; and UCB Pharma S.A.
Speakers Bureau: Alnylam Pharmaceuticals, Inc.; Annexon, Inc.; argenx; Janssen Global Services, LLC; Novartis AG; Roche; and Sanofi
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
John Jones, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
JC-030-082924-90
